Biotech

News

Dr Andrew Anzalone, Prime Medicine co-founder and head of platform development

Gene-editing firm Prime Medicine files $140m public offer

Gene-editing biotech Prime Medicine has priced a follow-on public offering, hoping to raise $140 million to advance its pipeline of one-shot therapies for severe genetic d

News

Earlybird principal Dr Christoph Massner

VC Earlybird Health raises €173m for healthtech companies

Venture capital group Earlybird has launched its second health fund with €173 million ($185 million) at its disposal to fund companies in the health technology area, more

News

Dermatology pharma Alys launches with $100m from Medicxi

European life sciences investor Medicxi has bundled together six privately-held companies with dermatology medicines in development under a single drugmaker – called Alys

News

Kyverna prices its IPO, seeking $319m for its cell therapies

Kyverna Therapeutics has announced the pricing of its initial public offering, and in another sign of the improving biotech financing environment has raised its target pro

R&D

Brighter times ahead for biotech in 2024?

The biotech industry experienced heady highs in early 2021, but has since suffered from a tight financial climate that has brought bankruptcies and widespread redundancies.

R&D